Likuiditas cepet anixa.com (ANIX)

Anixa Biosciences, Inc. (ANIX) focuses on developing cutting-edge immunotherapies to combat ovarian and breast tumors, backed by a robust scientific foundation. However, high laboratory expenditures during the testing phase are weighing on current earnings, with the figure standing at 8.74. The share price history clearly illustrates the price action of this asset. The company's financial stability remains questionable due to a lack of sales and a reliance on external R&D funding.

Investors seek fundamental guarantees of business resilience during periods of high uncertainty. This quick ratio is calculated by dividing the sum of cash and accounts receivable by current liabilities, completely excluding illiquid inventories. The trend of this indicator demonstrates a company's actual ability to settle debts instantaneously. For Anixa Biosciences, Inc. (ANIX), such liquidity is critical for funding oncology research and maintaining operational activities until new grants are secured.